Phospholipid-8-Profile IgG/IgM ELISA Kit

Sample

Serum

Species Reactivity

Human

Detection Method

ELISA

Intended Use

The Phospholipid-8-Profile IgG/IgM ELISA Kit is used for the separate quantitative determination of IgG and / or IgM antibodies to phospholipides (cardiolipin, phosphatidyl-serine, -inositol, -ethanolamine, phosphatidic acid and β₂ glycoprotein I) in human serum for the diagnosis of anti-phospholipid antibody syndrome (APAS).

Contents of Kit

Storage

The kit should be stored at 2-8°C upon receipt. After opening all kit components are stable for at least 2 months, provided proper storage.

Precision

Intra-Assay coefficient of variation (CV): 20-fold determination:

Inter-Assay coefficient of variation (CV): 5 different runs of 10-fold determinations:

Sensitivity

The analytical sensitivity of this assay was determined at 1.0 U/ml.

General Description

APAS is an autoimmune disorder comprising such clinical symptoms like arterial or venous thrombosis, thrombocytopenia and recurrent fetal loss. Primary APAS as well as systemic lupus erythematosus (SLE) are characterized by the appearance of autoantibodies to negatively charged phospholipids. Although significance and pathological relevance of phospholipid antibodies are not completely revealed yet, the detection of such autoantibodies is widely established and plays an important role in the diagnostics of systemic autoimmune diseases.
Unlike phospholipid antibodies which appear in some infectious disease patients autoimmune patients exhibit phospholipid antibodies that seem to recognize phospholipids in association with plasma protein cofactors such as β₂ glycoprotein-I (β₂ GP-I) (apolipoprotein H). β₂ GP-I, a serum protein with a molecular weight of 50 kDa, affects platelet aggregation and coagulation. The positively charged fifth domain of β₂ GP-I interacts with negatively charged phospholipids such as Cardiolipin. This interaction results in conformational changes of the protein and the creation of new epitopes apparently recognized by autoimmune phospholipid autoantibodies.